Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...
MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung ...
While chronic obstructive pulmonary disease can make exercise more challenging, regular physical activity may actually improve your symptoms and make it easier to perform everyday tasks. In addition ...
Zacks Investment Research on MSN
GSK gets EU approval for expanded use of Nucala in COPD
GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...
Researchers at the UNC School of Medicine have developed a tool that can identify airway mucus abnormalities in patients with ...
November is National Chronic Obstructive Pulmonary Disease Awareness Month. It’s time to raise awareness about lung disease within our communities. By understanding the causes, reducing our risk ...
GSK (GSK) on Friday announced that the European Commission has approved its Nucala asthma therapy for patients with chronic ...
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterised by persistent airflow limitation and chronic inflammation. Beyond its primary pulmonary manifestations, ...
Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...
GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease: London, UK Saturday, February 7, 2026, 09:00 Hrs [IST] GSK plc announced the E ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results